Review Article
Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
Table 2
Ongoing treatment studies evaluating MoAb treatment in ovarian cancer patients.
| | Protocol number | Disease stage | Target therapy | Treatment | Study phase | PI |
| | NCT00565851 (GOG-213) | Recurrent | Bevacizumab | Arm I: | Phase III | Coleman RL, MD | | Carboplatin + Paclitaxel/Docetaxel every 3 weeks | | Arm II: | | Carboplatin + Paclitaxel/Docetaxel + Bevacizumab every 3 weeks |
| | NCT00483782 (ICON 7) | Primary | Bevacizumab | Arm I: | Phase III | Perren TJ, MD | | Carboplatin + Paclitaxel for 6 cycles | | Arm II: | | Carboplatin + Paclitaxel + Bev for 6 cycles + Bev for 12 cycles |
| | NCT00849667 | Recurrent | Farletuzumab | Arm I: | Phase III | Morphotek, Inc | | Carboplatin + Taxane + Farletuzumab 1.25 mg/kg | | Arm II: | | Carboplatin + Taxane + Farletuzumab 2.5 mg/kg | | Arm III: | | Carboplatin + Taxane + Placebo |
| | NCT00951496 | Primary | Bevacizumab | Arm I: | Phase III | Joan L. Walker, MD | | Carboplatin + Paclitaxel + bevacizumab for 6 cycles + bev until progression/recurrence | | Arm II: | | Carboplatin + Paclitaxel + bevacizumab for 6 cycles | | Arm III: | | Carboplatin + Paclitaxel + bevacizumab for 6 cycles |
| | NCT00976911 | Primary | Bevacizumab | Arm I: | Phase III | Hoffmann-La Roche | | Topotecan + Paclitaxel + liposomal doxorubicin | | Arm II: | | Bevacizumab + Topotecan + Paclitaxel + liposomal doxorubicin |
| | NCT01081262 | Primary | Bevacizumab | bevacizumab | Phase III | Martin E. Gore, MD | | capecitabine | | carboplatin | | oxaliplatin | | paclitaxel | | Procedure: quality-of-life assessment |
| | NCT01167712 | Primary | Bevacizumab | Arm I: Carboplatin + Paclitaxel | Phase III | John K. Chan, MD | | Arm II: Carboplatin + Paclitaxel |
| | NCT01239732 | Primary | Bevacizumab | Arm I: Carboplatin + Bevacizumab + Paclitaxel | Phase III | Hoffmann-La Roche |
|
|
